| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T4 |
0-302 |
Sentence |
denotes |
Hidradenitis suppurativa (HS) is a chronic disabling inflammatory skin disease that, in moderate to severe cases, usually requires the use of systemic antibiotics, retinoids, and immunosuppressants/immunomodulants including adalimumab, the first‐approved anti‐tumor necrosis factor‐alpha (TNF)‐α agent. |
| T5 |
303-507 |
Sentence |
denotes |
Nevertheless, the presence of autoimmune conditions, particularly systemic lupus erythematosus (SLE), may represent a contraindication to the use of TNF‐α inhibitors due to the risk of drug‐induced lupus. |
| T6 |
508-680 |
Sentence |
denotes |
1 Thus, the unique association of HS with SLE may require the off‐label use of immune‐targeted therapies that is cautiously monitored during the current COVID‐19 pandemic. |
| T7 |
681-831 |
Sentence |
denotes |
We report one patient with HS and SLE who developed COVID‐19 infection during treatment with off‐label secukinumab associated with hydroxychloroquine. |
| T8 |
832-967 |
Sentence |
denotes |
Since COVID‐19 infection was diagnosed, secukinumab was interrupted, and azithromycin was combined with hydroxychloroquine for 2 weeks. |
| T9 |
968-1146 |
Sentence |
denotes |
When COVID‐19‐related symptoms completely resolved, nasopharyngeal swab results were negative and secukinumab therapy was reintroduced after 8 weeks from the last administration. |
